Decreased microglial activation in MS patients treated with glatiramer acetate

  • Ratchford C. J.; Hammoud, D. A.; Pomper, M. G.; Shiee, N.; McGready, J.; Pham, D. L.; Calabresi, P. A. J
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Activated microglia are thought to be an important contributor to tissue damage in multiple sclerosis (MS). The level of microglial activation can be measured non-invasively using [(11)C]-R-PK11195, a radiopharmaceutical for positron emission tomography (PET). Prior studies have identified abnormalities in the level of [(11)C]-R-PK11195 uptake in patients with MS, but treatment effects have not been evaluated. Nine previously untreated relapsing-remitting MS patients underwent PET and magnetic resonance imaging of the brain at baseline and after 1 year of treatment with glatiramer acetate. Parametric maps of [(11)C]-R-PK11195 uptake were obtained for baseline and post-treatment PET scans, and the change in [(11)C]-R-PK11195 uptake pre- to post-treatment was evaluated across the whole brain. Region-of-interest analysis was also applied to selected subregions. Whole brain [(11)C]-R-PK11195 binding potential per unit volume decreased 3.17% (95% CI: -0.74, -5.53%) between baseline and 1 year (p = 0.018). A significant decrease was noted in cortical gray matter and cerebral white matter, and a trend towards decreased uptake was seen in the putamen and thalamus. The results are consistent with a reduction in inflammation due to treatment with glatiramer acetate, though a larger controlled study would be required to prove that association. Future research will focus on whether the level of baseline microglial activation predicts future tissue damage in MS and whether [(11)C]-R-PK11195 uptake in cortical gray matter correlates with cortical lesion load.

Author-supplied keywords

  • Adult
  • Female
  • Glatiramer Acetate
  • Humans
  • Immunosuppressive Agents/*therapeutic use
  • Male
  • Microglia/*drug effects/*metabolism
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting/*drug ther
  • Peptides/pharmacology/*therapeutic use
  • Protein Binding/physiology
  • Treatment Outcome

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • J N.; Endres Ratchford C. J.; Hammoud, D. A.; Pomper, M. G.; Shiee, N.; McGready, J.; Pham, D. L.; Calabresi, P. A.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free